Safety, Tolerability and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients
This study is designed as a three-part trial to evaluate the safety of a novel depot formulation of iloperidone, compare two depot dosage forms, and perform dose ranging of one chosen form in support of a monthly depot dosing regimen. In Phase A, the study is designed to evaluate the safety of a crystalline iloperidone depot formulation. In Phase B, the pharmacokinetic and safety profile of two depot clinical dosage forms will be compared, and one form will be selected for assessment in Phase C. Phase C of this study is designed to define the dose-exposure relationship of the selected form and to provide information that will permit a comparison of the risk-benefit ratio of several doses of the study drug to enable optimal dose selection for later studies.
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Iloperidone, Iloperidone, Iloperidone, Iloperidone, Iloperidone, Iloperidone, Iloperidone
Novartis Investigative Site
Results (where available)
- Source: http://clinicaltrials.gov/show/NCT01348100
- Information obtained from ClinicalTrials.gov on April 11, 2013
Medical and Biotech [MESH] Definitions
A chronic form of schizophrenia characterized primarily by the presence of persecutory or grandiose delusions, often associated with hallucination.
A type of schizophrenia characterized by abnormality of motor behavior which may involve particular forms of stupor, rigidity, excitement or inappropriate posture.
An obsolete concept, historically used for childhood mental disorders thought to be a form of schizophrenia.
A type of schizophrenia characterized by frequent incoherence; marked loosening of associations, or grossly disorganized behavior and flat or grossly inappropriate affect that does not meet the criteria for the catatonic type; associated features include extreme social withdrawal, grimacing, mannerisms, mirror gazing, inappropriate giggling, and other odd behavior. (Dorland, 27th ed)
A benzocycloheptapyridoisoquinolinol that has been used as an antipsychotic, especially in schizophrenia.
The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exace...
This study will create a DNA collection with blood samples from families with at least two siblings who have schizophrenia symptoms. This collection will help scientists identify genes tha...
Schizophrenia has long been known to be an illness with significant evidence for a genetic predisposition. The purpose of this study is to determine the genetic abnormalities that cause c...
The proposed study would evaluate the benefits of riluzole add-on treatment to patients with schizophrenia who are already receiving medications, but still experience symptoms. Neuroprotec...
The objective of this study is to evaluate the effectiveness of a marketed drug in the treatment of schizophrenia, as an add-on therapy to antipsychotics over a 12-week period. Subjects wi...
Purpose The pharmacology, pharmacokinetics, pharmacogenomics, clinical efficacy, and safety and tolerability profile of iloperidone for the treatment of schizophrenia are reviewed. Summary Iloperidone...
This article briefly reviews the novel atypical second-generation antipsychotic drugs iloperidone (Fanapt(®)), asenapine (Saphris(®)), and lurasidone (Latuda(®)), all of which have been approved by...
Introduction: Meta-analyses are a convenient way for clinicians and researchers to review data regarding different interventions. Meta-analyses can overcome many of the limitations of individual studi...
RATIONALE: Autism and related pervasive developmental disorders (PDD) are characterized by impairments in social interaction and communication, restricted interests, and repetitive and stereotyped pat...